Drug Trial Radar · NCT00806026
Long Term Study Of Pregabalin In Idiopathic Restless Legs Syndrome Patients
Last checked: Nov 20, 2026Latest source record: Jan 26, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
731
Actual
Start
Dec 2008
Primary completion
May 2011
Study completion May 2011
Sponsor
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Pfizer (PFE)
- Sponsor type
- Industry
- First posted
- Dec 10, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This purpose of this study is to investigate the efficacy and tolerability of pregabalin in treating idiopathic RLS patients for up to 12 months.
Conditions
- Idiopathic Restless Legs Syndrome
Interventions
placebo and pregabalinDrug
following 3 months placebo treatment, subjects are to be re-distributed to pregabalin 300 mg per day for 9 months. Both placebo and pregabalin are to be administered orally once a day, 1-3 hours before bedtime.
pramipexolDrug
following 3 months placebo treatment, subjects are to be re-distributed to pramipexol 0.25mg per day for 9 months. Both placebo and pramipexol are to be administered orally once a day, 1-3 hours before bedtime.
pramipexolDrug
following 3 months placebo treatment, subjects are to be re-distributed to pramipexol 0.5mg per day for 9 months. Both placebo and pramipexol are to be administered orally once a day, 1-3 hours before bedtime.
PregabalinDrug
pregabalin 300 mg, orally administered once a day, 1- 3 hours before the bedtime for 12 months
pramipexolDrug
pramipexol 0.25 mg, orally administered once a day, 1- 3 hours before the bedtime for 12 months
pramipexolDrug
pramipexol 0.5 mg, orally administered once a day, 1- 3 hours before the bedtime for 12 months
Primary outcomes
What the sponsor says the trial is designed to measure.
- Restless Legs Syndrome (RLS) Symptom SeverityTime frame: Baseline
- Change From Baseline in the RLS Symptom Severity at Week 12Time frame: Baseline, Week 12
- Percentage of Participants Responding to Treatment at Week 12Time frame: Week 12
- Percentage of Participants With AugmentationTime frame: Baseline up to Week 52
Locations
110 sites in 9 countries. Site status is shown where the registry gives one.
Pfizer Investigational Site
Birmingham, Alabama
Pfizer Investigational Site
Jasper, Alabama
Pfizer Investigational Site
Tuscaloosa, Alabama
Pfizer Investigational Site
Glendale, Arizona
Pfizer Investigational Site
Phoenix, Arizona
Pfizer Investigational Site
Phoenix, Arizona
Pfizer Investigational Site
Little Rock, Arkansas
Pfizer Investigational Site
Little Rock, Arkansas
Pfizer Investigational Site
Northridge, California
Pfizer Investigational Site
Redondo Beach, California
Pfizer Investigational Site
San Diego, California
Pfizer Investigational Site
San Diego, California
Pfizer Investigational Site
Santa Monica, California
Pfizer Investigational Site
Torrance, California
Pfizer Investigational Site
Aurora, Colorado
Pfizer Investigational Site
Boca Raton, Florida
Pfizer Investigational Site
Hallandale, Florida
Pfizer Investigational Site
Miami, Florida
Pfizer Investigational Site
Pembroke Pines, Florida
Pfizer Investigational Site
South Miami, Florida
Pfizer Investigational Site
Atlanta, Georgia
Pfizer Investigational Site
Overland Park, Kansas
Pfizer Investigational Site
Louisville, Kentucky
Pfizer Investigational Site
Baton Rouge, Louisiana
Pfizer Investigational Site
Chevy Chase, Maryland
Pfizer Investigational Site
Newton, Massachusetts
Pfizer Investigational Site
Southfield, Michigan
Pfizer Investigational Site
Minneapolis, Minnesota
Pfizer Investigational Site
Princeton, New Jersey
Pfizer Investigational Site
New York, New York
Pfizer Investigational Site
Salisbury, North Carolina
Pfizer Investigational Site
Salisbury, North Carolina
Pfizer Investigational Site
Winston-Salem, North Carolina
Pfizer Investigational Site
Cincinnati, Ohio
Pfizer Investigational Site
Columbus, Ohio
Pfizer Investigational Site
Oklahoma City, Oklahoma
Pfizer Investigational Site
Lafayette Hill, Pennsylvania
Pfizer Investigational Site
Austin, Texas
Pfizer Investigational Site
Dallas, Texas
Pfizer Investigational Site
Houston, Texas
Showing 40 of 110 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.